plerixafor has been researched along with Injury, Myocardial Reperfusion in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Limbourg, FP | 1 |
| Asahi, M; Clarke, T; Hagiwara, N; Ii, M; Ito, A; Jujo, K; Kamide, C; Klyachko, E; Losordo, DW; Misener, S; Qin, G; Renault, MA; Roncalli, J; Sekiguchi, H; Tanaka, T; Thorne, T; Tongers, J; Tsurumi, Y | 1 |
2 other study(ies) available for plerixafor and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
A quick fix?: Short-term CXC-chemokine receptor 4 inhibition redistributes proangiogenic bone marrow cells to ischemic myocardium in an endothelial nitric oxide synthase--dependent fashion.
Topics: Animals; Benzylamines; Cyclams; Female; Heterocyclic Compounds; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Receptors, CXCR4 | 2013 |
CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism.
Topics: Animals; Benzylamines; Bone Marrow Transplantation; Cardiotonic Agents; Cyclams; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Receptors, CXCR4; Recovery of Function; Signal Transduction | 2013 |